$SAN News Article - Dupixent (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
https://marketwirenews.com/news-releases/dupi...56452.html